...
首页> 外文期刊>South African medical journal = >Time to fibrinolytics for acute myocardial infarction: Reasons for delays at Steve Biko Academic Hospital, Pretoria, South Africa
【24h】

Time to fibrinolytics for acute myocardial infarction: Reasons for delays at Steve Biko Academic Hospital, Pretoria, South Africa

机译:纤溶酶治疗急性心肌梗死的时间:南非比勒陀利亚史蒂夫·比科学术医院延误的原因

获取原文
           

摘要

BACKGROUND. Fibrinolytic therapy is a time-critical intervention proven to reduce mortality and morbidity in patients with ST-elevation myocardial infarction (STEMI). Limited data exist in South Africa (SA) regarding time to fibrinolytic therapy for STEMI patients and reasons for delayed therapy. OBJECTIVES. To establish the proportion of STEMI patients receiving fibrinolytic agents at Steve Biko Academic Hospital (SBAH), Pretoria, SA, identify any delays to receiving fibrinolytic agents, and uncover reasons for those delays. The number of lives lost as a result of these delays was calculated. METHODS. This prospective, observational study included 100 consecutive patients presenting with a STEMI to SBAH. Using a researcher- administered questionnaire, the times from symptom onset to receipt of fibrinolytic therapy and the reasons for delays were documented. The number of lives lost was then calculated. RESULTS. Only 37% of patients received fibrinolytic therapy and only 3% received the medication within 1 hour. The median total delay in receiving fibrinolytic therapy was 270 minutes (range 45 - 584). The median time delays from onset of symptoms to call for help, between calling for help and arriving at hospital, and from hospital arrival to fibrinolytic agent administration, were 35 minutes (5 - 1 185), 55 minutes (12.5 - 670) and 62.5 minutes (16.5 - 282), respectively. Numerous delays were identified at all stages, with patient and transport delays being most significant. Strikingly, an additional 32 patients per 1 000 treated could have been saved if a fibrinolytic agent had been administered within 1 hour. CONCLUSIONS. This study highlights the important problem of delayed or non-administration of fibrinolytic therapy at a tertiary hospital. The problems identified will contribute to the implementation of a robust STEMI management network in SA, similar to those in developed countries.
机译:背景。纤溶治疗是一项对时间至关重要的干预措施,已被证明可降低ST抬高型心肌梗死(STEMI)患者的死亡率和发病率。南非(SA)关于STEMI患者进行纤溶治疗的时间以及延迟治疗的原因的数据有限。目标为了确定在南卡罗来纳州比勒陀利亚的史蒂夫·比科学术医院(SBAH)接受纤溶剂治疗的STEMI患者的比例,确定任何接受纤溶剂治疗的延误,并找出延误的原因。计算了由于这些延误而丧生的人数。方法。这项前瞻性观察性研究纳入了100例连续性SBAH患者。使用研究人员管理的问卷,记录了从症状发作到接受纤溶治疗的时间以及延误的原因。然后计算了丧生人数。结果。仅37%的患者在1小时内接受了纤溶治疗,只有3%的患者接受了药物治疗。接受纤溶治疗的中位总延迟时间为270分钟(范围45-584)。从症状发作到寻求帮助,从寻求帮助到到达医院之间以及从到达医院到纤溶剂给药之间的中值时间延迟分别为35分钟(5-1185),55分钟(12.5-670)和62.5分钟(16.5-282)。在所有阶段都发现了许多延误,其中患者和运输延误最为明显。令人惊讶的是,如果在1小时内使用纤维蛋白溶解剂,则每1000例中可以挽救32名患者。结论。这项研究突出了三级医院纤溶治疗延迟或不服用的重要问题。与发达国家类似,发现的问题将有助于在南非实施强大的STEMI管理网络。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号